U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Go back to U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 1.22 -0.04 (3.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.26 | 52 Week High | $13.20 | |||
| Open | $1.23 | 52 Week Low | $7.00 | |||
| Day High | $1.25 | P/E | N/A | |||
| Day Low | $1.19 | EPS | $0.00 | |||
| Volume | 1,626,718 | |||||
